Clinical presentation of SNCA Duplication Parkinsonism in a Family Kindred
Objective: To report phenotype variability in a family with SNCA duplication associated Parkinsonism. Background: Pathogenic variants in SNCA, the gene coding for α-synuclein, cause familial…Myelination relevant plasma microRNA biomarkers identified via an innovative data analytic scheme for differential diagnosis of MSA, an Oligodendroglial Synucleinopathy
Objective: To establish an inclusive data analytic scheme to identify and characterize plasma microRNA biomarkers with pathophysiological significance for differentiating the atypical Parkinsonian, Multiple System…IkT-148009 as a potential disease-modifying therapy in PD
Objective: Modeling Parkinson’s disease in mice suggests c-Abl activation is required for PD initiation and progression, and therefore inhibition of c-Abl could be a strategy…in vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson’s disease
Objective: To evaluate pathologic alpha-synuclein (AS) seeding activity with Real-time quaking-induced conversion (RT-QuIC) assay using formalin fixed paraffine-embedded (FFPE) tissue of GI tract in Parkinson's disease (PD)…Effect of CDNF in a novel combination stressor model of Parkinson’s disease
Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease
Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…α-Synuclein in sympathetic nerve fibers distinguishes PRKN from LRRK2 and other genetic forms of Parkinson’s Disease
Objective: This cross-sectional observational study compared magnitudes of intra-neuronal deposition of α-synuclein in common and rare genetic forms of Parkinson’s disease. Background: Cytoplasmic inclusions of…ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease
Objective: We report on the pharmacological characteristics of ABBV-0805 (BAN0805), a monoclonal antibody that exhibits a high selectivity for human α-synuclein oligomers and very low…Gut dysbiosis in Parkinson’s disease with motor complications
Objective: We aimed to identify gut dysbiosis in Parkinson's disease patients with motor complications. Background: Recently, several evidences suggest that the gut microbiota is associated…α-synuclein expression is not mediated by β2-adrenoreceptor modulation in human dopaminergic cells
Objective: Modulation of the β2-adrenoreceptor (also called the β2-adrenergic receptor or β2-adrenoceptor) has been reported to regulate SNCA expression. We sought to determine the expression…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 60
- Next Page »